The FDA has approved dupilumab (Dupixent, Sanofi and Regeneron) to treat eosinophilic esophagitis in patients 12 years and older weighing more than 40 kilograms.
This approval makes dupilumab the first drug approved for the disorder, which has been growing in incidence worldwide since the earliest case reports published in the 1970s (Gastroenterol 2018;154[2]:319-332). Current estimates say 300,000 patients in the United States are living with EoE, according to Sanofi.
“As